Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's see how long and strong you are when PLUG keeps edging lower. Do you have an exit price or will you be long and strong at 5 or 4 or 3.
Plug is a trading stock. The fundamentals,company incompetence and the fact that what they sell are fork lifts ,although I will give you they may be about to sell more (at a loss per unit and service contract) does not bode well if you are in it as an investor.
Still the best of luck.
Remember who presented yesterday. Your CEO, who consistently over promises ,teases with I can't say right now,but will in the future. The weakness in the stock price is reflecting his ability to deliver.
GLTA
I recently rode the stock up to 11+ and after the presentation immediately bought puts till May after the earnings call.I play it as I see it. "Playing the stock market" is anticipating the near term direction. Investing in the stock market is another mindset.
Loaded up on puts. That call and the CEO's presentation takes the cake for one of the worst I've ever heard.
He couldn't even pronounce Hyundai correctly.
And only two questions from two lame analysts.
PATHETIC.
HEY LONGS,better get to the exit doors real quick or you won't get out before the panic and reality hits you square in the kisser.
And when you day dreamers wake up there will be no one to sell your over hyped shares to.
MORE NEWS
< Back to Market News
Related Quotes
Sym. Price Chg.
GOGO Trade
News 17.7896 0.7996 Gogo Expands Global Commercial Airline Sales Team
Apr 17, 2014 10:21:00 (ET)
Gogo Now has Feet on the Street Coverage Around the World
ITASCA, Ill., April 17, 2014 /PRNewswire/ -- Gogo (NASDAQ: GOGO), a leading aircraft communications service provider to the global aviation industry, announces today that it has expanded its global sales team, which now includes more than 20 sales and support staff with physical presence in the United Kingdom, Switzerland, Spain, Israel, Singapore and Japan.
"We continue to invest in our global expansion efforts and we have been pleased with our ability to hire some of the best and brightest in this industry," said Niels Steenstrup, senior vice president of Global Airline sales. "We have experienced industry professionals dedicated to each region of the world."
Most recent additions to the team include:
Ray Villar - Ray is the new regional sales director for Latin America. Ray has more than 16 years in sales and marketing experience, as well as business development experience, in both the telecommunications and aerospace industries. He started his career as a Navy commissioned officer and dedicated his military career to communications requirements. He has held senior management positions at Alcatel-Lucent, EMS Aviation, and Honeywell before joining Gogo.
Nick Silvester -- Nick is the director of sales for the Middle East and Africa. Nick has extensive customer support, sales and business development experience in in-flight connectivity and entertainment. Prior to joining Gogo, Nick has held senior positions with Panasonic Avionics, Thales and Honeywell. Nick is now based in Dubai.
Soong Teck Kuay -- Kuay joins Gogo as director of business development for Asia Pacific. Prior to Gogo, Kuay was head of in-flight entertainment sales for Thales in Asia and spearheaded their wins in Air India, Indian Airlines, HNA, VNA and JAL amongst others. He is currently based in Singapore.
"Ray, Nick and Kuay are great additions to our expanding team of sales professionals in Gogo's global organization," added Steenstrup. "I'm confident that these additions will give us added support in gaining new international commercial airline partnerships."
Commercial airlines interested in finding out more about Gogo's products and services can reach the global sales team at airlinesales@gogoair.com
About Gogo
Gogo is the global leader of in-flight connectivity and wireless in-flight digital entertainment solutions. Using Gogo's exclusive products and services, passengers with Wi-Fi enabled devices can get online on more than 2,000 Gogo equipped commercial aircraft. In-flight connectivity partners include Aeromexico, American Airlines, Air Canada, AirTran Airways, Alaska Airlines, Delta Air Lines, Japan Airlines, United Airlines, US Airways and Virgin America. In-flight entertainment partners include Aeromexico, American Airlines, Delta Air Lines, Japan Airlines, Scoot and US Airways. In addition to its commercial airline business, Gogo has more than 6,300 business aircraft outfitted with its communications services.
Back on the ground, Gogo's 700+ employees in Itasca, IL, Broomfield, CO and various locations overseas are working to continually redefine flying as a productive, socially connected, and all-around more satisfying experience. Connect with Gogo at www.gogoair.com, on Facebook at www.facebook.com/gogo and on Twitter at www.twitter.com/gogo.
Media Relations Contact: Investor Relations Contact:
Steve Nolan Varvara Alva
630-647-1074 630-647-7460
pr@gogoair.com ir@gogoair.com
Logo - http://photos.prnewswire.com/prnh/20110715/CG34837LOGO
SOURCE Gogo
/Web site: http://www.gogoair.com
(END) Dow Jones Newswires
April 17, 2014 10:21 ET (14:21 GMT)
Just out today at 9:15 am
*DJ Gogo Inc Raised to Overweight From Neutral by JPMorgan >GOGO
If you trade 500 k a day you wouldn't be on these boards.
You are a fraud.
At that level you would have a better use of your time.
Get the book.
Between 2013 to 2016.
There are too many factors to be precise.
The book is available at your public library or go to the internet and find out how to get a copy.
David Wiedemer PhD has the credentials and gravitas to be respected.
Get the book because the ramifications can't possibility be explored on a forum like this.
GLTA
You need to reference the book yourself,but looking at it now,it says a loss of confidence in US holdings by foreign investors could begin from 2013 and increasing over time with the likelihood of a mass exit by or before 2016. But let me repeat you need to read the book to get a clear understanding from where they are coming from. You need to due your own DD.
I can't give you an adequate answer on this forum,especially since I am one finger typing on my Ipad.
Do your research and get a copy of this book. Then make your own decisions.
Author is David Wiedemer PhD. Wrote two books
1st is America's Bubble Economy which predicted the 2008 decline and the reasons why.
Then followed up with Aftershock which predicts the next global financial meltdown that should be far worst then 2008.
BTW. you can always short against the box and hold your present price level.
It's a conservative way of protecting your self.
If you are not aware of this investment insurance Check it out on google.
Unfortunately,I think many new investors are not aware of this tactic.
Simply put-net gains and net losses are neutralized.
If you get the direction right like with NVAX and took that position just a little while ago you would be in a much better position then holding on to your long term shares.
Hope this is helpful.
Read "aftershock" check it out online or get it at your local library. It will open your eyes to what really " is"
Yes, the market forces can easily overcome fundamentals. Just look at history. That was not part of your post.
Technicals are interpretive. Fundamentals are reality. No one can predict the future only through good due diligence and objectifying the data at hand can one realistically get a decent result and that is not guaranteed.
"technicals drive stocks,not news".
Man talk about getting it backwards.
Technicals only offer a vague reference to the "possible" future direction of price based on interpretive understanding of past events. So technicals may be helpful in entry and exit points, simply because others use the same information to make decisions. That makes technicals selfulling.
News is exactly what most of you are waiting on.
Unfortunately you are relying on a CEO that over promises and under delivers.
Wake fools.
This may help ease the pain,maybe.
Long term speculative holdings are risky and can get you were it hurts,real bad.
But the fundamentals are still intact.This is what happens when major "risk off" shift!s occur.
Wish I saw it just a few short weeks ago. As I see it we're in for the long haul now.
Still I am worried because the book "Aftershock" by David Wiedemer, PhD doesn't hold out much promise for the present and near term future for the world economies,especially America.
It's a disturbing read written by a team that saw the 2008 disaster well before it happened. aftershock is the second edition to America's Bubble Economy".
Biotech stocks have posted some ugly losses lately.
Photo by John Moore/Getty Images
If you’ve been following the markets, then you’ll know that the last few weeks have been ugly ones for biotech stocks. The Nasdaq Biotechnology Index has shed 17.8 percent since March 18, dragged down by losses in big names like Gilead Sciences, Alexion Pharmaceuticals, and Biogen Idec. On April 4, investors pulled $372 million from the biggest biotech-focused exchange traded fund—its worst ever redemptions.
ALISON GRISWOLD
Alison Griswold is a Slate staff writer covering business and economics.
Follow
In spite of all that, this isn’t necessarily the bio-pharmapocalypse.
“The biotech sector got a little bit ahead of itself and we’re now in a period of extended—and I mean weeks, months, not eternal—profit-taking or consolidation,” says Ted Tenthoff, managing director and senior biotechnology research analyst at Piper Jaffray.
To put the current sell-off in perspective, biotech indexes soared more than 200 percent over the past five years. Their gains easily doubled those seen by the broader market in the same period, and lately investors had started questioning how long that momentum could last. “We’ve had, frankly, an astounding move higher,” Tenthoff says.
With all that upward movement, the biotech sector was long overdue for a pullback. And that’s what we’re seeing now. Investors are selling and profit-taking to consolidate their positions, which in turn drives down the market. But once that’s finished, the sector might have plenty more room to run.
Tenthoff argues that we’re in a “golden age” of biotech for three main reasons:
Big-cap biotech stocks like Gilead, Alexion, and Biogen are among the fastest growing companies period. If you’re a big-cap growth fund manager, you can’t ignore biotech right now.
The sector is seeing an “unprecedented” level of productivity in terms of new drug approvals and late-stage projects.
Big pharmaceutical and biotech companies have “mountains of cash” sitting on their balance sheets.
“I still think we’re in the middle innings of a multi-year biotech bull market,” he says. “This is a painful but necessary pause as we consolidate our recent gains before we move higher.”
It’s interesting to note that the recent sell-off has not been due entirely to losses in biotech, but more broadly part of a risk-off investing shift from “growth” to “value.” Companies with growth stocks are expected to show above-average growth in revenues, earnings, or cash flow, while value stocks are ones investors think the market is overlooking.
In a Monday report, Morgan Stanley’s U.S. equity researchers observed that, historically, value stocks tend to keep doing well following strong value rallies (like the one we’ve had lately) and growth stocks won’t necessarily bounce right back. “The expectation that many investors we talked to last week have—of a growth rebound following a run-up in value stocks—is not borne out by history,” they write.
In the aftermath of “extreme value rallies,” Morgan Stanley finds that energy and staples outperform, while technology and telecom underperform. Health care, which includes biotech, falls somewhere on the lower-middle end of the spectrum.
Morgan Stanley has trimmed its exposure to technology stocks by 2 percent, but continues to place a huge overweight on health care and pharmaceuticals like Bristol-Myers Squibb. That should probably be somewhat reassuring—they’re not jumping out of biotech yet, either.
4
19
5
The shares are borrowed and must be bought back to cover the short.
There is nothing evil about the concept.
When there is abuse then the SEC should step in,unfortunately they seldom do. The real problem is naked shorting with in borrowed shares creating artificial supply causing the pricing pressure.
Well, the price below 2 was enough for me to pick up a little piece.
Wallet has money and will wait and see.
General market "mentality" is up for grabs.
Think the Ukraine "problem" can seriously affect CPST.
NO ONE ever knows the future.
We do the best we can.
GLTA
ROTATION. Pure and simple. Markets determine where the money flows. Today value, yesterday biotech. The thing is when does the rotation say "Enough"- Let's get back into biotech-"It's overdone".
THAT is the challenge. Fundamentals matter, but when you are dealing with the "potential" of a blockbuster,as a long, hold your chops and do your DD.
GLTA
nypete
Remember if any one of these 5 holders of the stock want to unload that is a huge supply that retail investors can not assimilate.
The PPS must come down. I strongly advise to wait and see some level of a bottom. Fundamentally,I like this company,but can not overlook the action that markets can impose to make holding a long position PAINFUL. I have had dead money many times in my investing time, but never in my trading. There is a RISK in holding long over time based on fundamentals, much less so when you are trading short term (days or weeks). Been there done that.
GLTA
Yes,I agree,but the severity of the decline is the major rotation taking place recently,especially again today.
I own 2 bio techs with a nice pipeline and one even has earnings both getting creamed.
I trade daily and avoided doing my taxes because it's such a pain in the A&@.
Now it's less painful doing my taxes. Now that's bad.
Remember only 5 investors hold ~77% of the outstanding shares a the capital management firms are known for high turnover. I repeat that S.A.C. Capital recently closed down due to insider trading scandal held 6.13 percent of GOGO.
Go back a few posts and read my post as to the most likely reason.
If a stock is held by a few equity players that have a high turnover rate then you get what we have the last few days. Remember that pre market on Thurs. GOGO traded at 21.75 high on the Boeing news. I almost sold my trading position then,but wanted to see what the regular market would price it at. Guess what an immediate sell off that is continuing today. I am going to wait until this bases for a few days,no telling when the seller(s) are done.
I know GOGO can move big either way,that's why I like to trade it holding a core long term. Problem is the rotation taking place out of growth into value/dividend stocks. And there is the possibility of a severe correction that could happen any time.
Nypete
Unfortunately, GOGO I has a narrow investor base and it's my guess some of these investors are rotating out of growth stocks. This explains the price weakness that is sudden and severe.Below is some information that will show who the major holders are. Individuals and private equity firms even S.A.C Capital that was investigated by the government and can not hold assets from the public anymore.
nypete
HOLDINGS SUMMARY
Holdings
Total Number of Shares Held 88,019,731
Large Block Owners 103
Percent Shares Owned 103.50%
Percent Change in Ownership -0.12%
How does Ownership equal more than 100%?
1.30% Brokerage Firms
65.00% Investment Managers
37.20% Strategic Entities
3.50% Non-Institutional
Mouseover legend for more detail.
Regional Holdings
North America 102.60%
Asia 0.60%
Europe 0.30%
Monthly Share Rotation
Type Number of Shares Value of Change Shares Outstanding
Buyers 4/11/14 200 $4,108 0.00%
Sellers 4/11/14 102,100 $2,097,134 0.00%
TOP OWNERS
Concentration of Shares Held
103.50% Top Owners
101.40% Top 50 Owners
94.30% Top 20 Owners
87.60% Top 10 Owners
-3.50% Other Owners
Other Owners
Average Turnover Rating
Very High
High
Moderate
Low
Name Shares Held Position Value % of Total
Holdings Outstanding
Shares Owned Investment Style
Balyasny Asset Management LP 743.1 K $18.4 M 0.84 1.29% High
Collins (Timothy C) 876.1 K $22.4 M 1.00 1.56% Low
Cupps Capital Management, LLC 1.1 M $26.9 M 1.23 1.87% High
LeMay (Ronald T) 4.5 M $107.2 M 5.06 7.47% High
Northern Trust Global Investme... 7.4 M $183.8 M 8.41 12.81% Low
Ripplewood Holdings, LLC 27.6 M $386.1 M 31.40 26.92% High
S.A.C. Capital Advisors, LP 4.3 M $88.0 M 4.87 6.13% High
Thorne (Oakleigh L) 24.6 M $344.3 M 28.00 24.00% N/A
Townsend (Charles C) 1.4 M $20.5 M 1.61 1.43% N/A
Waddell & Reed Investment Mana... 2.0 M $48.7 M 2.23 3.40% Low
TOP MUTUAL FUND OWNERS
Top Mutual Fund Owners
2.05% Sector Specific
1.04% Index
0.70% Core Growth
0.56% Core Value
0.32% Aggres. Gr.
0.23% Growth
0.13% GARP
0.02% Specialty
Average Turnover Rating
Very High
High
Moderate
Low
Name Shares Held Position Value % of Total
Holdings Outstanding
Shares Owned Investment Style
BlackRock Small Cap Growth Equ... 190.0 K $3.9 M 0.22 0.27% Aggres. Gr.
Columbia Small Cap Growth Fund... 384.0 K $8.0 M 0.44 0.56% Core Growth
EQ/GAMCO Small Company Value P... 135.7 K $2.8 M 0.15 0.20% Core Growth
Ivy Science and Technology Fun... 939.0 K $23.3 M 1.07 1.62% Sector Specific
Ivy VIP Small Cap Growth Fund 200.5 K $5.0 M 0.23 0.35% Growth
Vanguard Small-Cap Index Fund 142.0 K $3.0 M 0.16 0.21% Index
Vanguard Total Stock Market In... 126.5 K $2.6 M 0.14 0.18% Index
Waddell & Reed Advisors Scienc... 712.2 K $17.7 M 0.81 1.23% Sector Specific
Wells Fargo Advantage Small Ca... 495.4 K $10.1 M 0.56 0.70% Core Value
iShares Russell 2000 ETF 175.9 K $3.7 M 0.20 0.26% Index
GOGO is considered a momo stock with hi vol.
Fundamentally sound, I loaded up below 19 Wednesday and unfortunately didn't unload on the pre market yesterday as the news with BA was announced driving the pre market price to 21.75
The drop from the open is all market related with rotation out from biotech and momo to more mature stocks.
If your an investor buying in pre- determined tranches below 20 is a good strategy.
If your a trader take your points when they are there.
GLTA
I am calling my reps. From my state to support HR bill supporting micro turbines with tax incentives similar to other alt. Energy sources. You should all do the same.
I' ll be adding on any weakness because of the macro weakness in the markets.
GLTA
Here it is:
Well,I am down at 2.06 today,got lucky yesterday and bought for a trade in 2.03 out 2.13. It's rare to catch the low and high by one penny (on the ask side.
It's a no brainer. Just hope that those in power recognize it.
I didn't bold the right part. It was the first sentence just before. Oh,well,I blame my I pad and a fat finger.
Here is Adam Gefvert's self described profile.
A CFA Charterholder, Adam is an independent investment consultant and stock trader, with a lean towards technology and biotech stocks. He looks for misunderstood companies and special situations.
Adam will only publish his research on Seeking Alpha that he believes will have an immediate impact on the stock.[The information has to be valuable and unrealized enough to cause a reaction or Adam will either not publish it, or will give his readers a warning. He values his reputation for delivering action-worthy information.
He has a BA in Bus/Econ from UC Santa Barbara and resides in New York City.
You can follow him on twitter @shiningboy
SNAPSHOT
Description: Investment Consultant. Trading frequency: Daily
Interests: Options, Stocks - long, Stocks - short
BOLD TEXT is for my emphasis.
Light-man,my bad. I was too busy on the sec site and did not go back to the IH site to see your updated post.
BigBake1 I booked market OpenInsider. Thanks for the reference. I too appreciate the color coding. Getting old I guess.
nypete
Looking good.
http://irdirect.net/filings/viewer/index/1000694/000120919114022921/
Just what you want to see before Phase 2 info. release.
nypete
And here is another Form 4. BTW both form 4's were admended. Evidently there was a mistake in filling out the form originally. My next post shows another Form 4 filed for 50,000 shares Dir. Douglas Richard
http://irdirect.net/filings/viewer/index/1000694/000120919114022919/
HERE IS THE SEC Form 4.
You are wrong. Stock was acquired.
http://irdirect.net/filings/viewer/index/1000694/000120919114022917/
New blog from a announced short on SA. Just came out.
http://seekingalpha.com/article/2108533-capstone-turbines-stock-is-more-bloated-than-plug-powers-ever-was
Let's see what affect,if any, he has.
nypete
Yes,I was not aware of it before. It saves some time to pull quite a bit of useful info. I bought some Oct 6 calls to hold more cash and still have exposure to any trial outcomes or other news.
BTW Mark Schaenebaum, a respected analyst on biotech, was on CNBC being interviewed on the Half Time show with the fast money crowd.
Here is a link:
http://video.cnbc.com/gallery/?video=3000261015
Sorry, this is the link I meant.
http://www.finviz.com/quote.ashx?t=nvax&ty=c&ta=1&p=d
Beat me to the punch BigBlake.LOL
I was doing some dd. You may not know this site,but it seems to consolidate useful info. on company blogs and news.
http://www.theflyonthewall.com/permalinks/entry.php/NVAXid1983913/NVAX-Novavax-CEO-buys-K-shares-CFO-buys-K-shares
I am and have been a long term holder based on fundamentals and up coming catalyst could be explosive for stock price upwards. Maybe because I read Aftershock by David Wiedemer ,who did predict the 2008 decline,based on the facts that most investors ignored, the time is coming when his prediction for the next wave down is showing the very signs he laid out in 2011. When a Tsunami hits the shore line,it's too late and all is gone,but if you had headed the birds and land animals you would have been saved.
I also own INO (another biotech) and they too have huge catalysts this year,but am not sanguine on the macro events ( China,Russia,Fed,lack of governmental leadership,etc) and the early signs of a major decline technically.
More importantly I have to admit that I sold out some of my NVAX position on the Feb. Highs,but started to re- establish to soon.Should have waited. Bought more around 4.20 to average down.
Anyway got my fingers crossed,just waiting to see what comes up near term. I am in too deep percentage wise of my portfolio in biotech. Guess that doesn't help my foreboding much.LOL
BEST TO ALL
Nypete
Sure looks like Modi is still selling. Has 9.5 mill. Is he getting out entirely? I added some today for a short term trade-didn"t happen! This stock needs a lot more time to base. Must wait and see the heavy selling stop. We still have China slowing down and if their next GDP growth rate slows down to the 6 to 6.5% level then that macro event doesn't bode well for global growth. Add to that the markets obvious dumping of recent gainers,momo stocks and social media stocks. And finally there is always our "friend" Vladimir P. taking advantage of his stranglehold over Europe and his disdain for our "president". Let me depress you some more-margined stock at very high levels,Company CEO's selling their own company's shares in record numbers and the public coming back into equity markets with their total assets over 40%.These are signs of a market that may be running out of buyers. Hope not, but it is what it is.
Fundamentally NVAX is in fine shape as far as I know,but do not forget stock pricing has more to do with human emotion then fundamental facts. We have been there before more then once. Keep history in mind and be careful.
Sorry to be the Debbie Downer.
GLTA
nypete
Hope your right. Bought some shares Friday at 5.96.
Love to trade PLUG.